文献速递母胎医学产科

胎儿先天性心脏病产前染色体微阵列分析:一项前瞻性队列研究

Prenatal chromosomal microarray analysis in fetuses with congenital heart disease: a prospective cohort study.
PubMed 文献 · Am J Obstet Gynecol · 2017-11-08

该前瞻性研究对602例产前先天性心脏病胎儿进行单核苷酸多态性微阵列分析,发现致病性染色体异常检出率为20.8%,其中52.0%为数目异常。合并其他结构异常或宫内生长迟缓的胎儿检出率显著高于孤立性先天性心脏病胎儿。作者认为染色体微阵列分析可作为产前诊断先天性心脏病的一线检测。

要点

  • 602例先天性心脏病胎儿中致病性染色体异常检出率为20.8%。
  • 合并其他结构异常组检出率48.9%,显著高于孤立性先天性心脏病组14.3%。
  • 合并宫内生长迟缓组检出率50.0%,显著高于孤立性先天性心脏病组14.3%。

核心结论

  • 作者认为染色体微阵列分析是一种可靠的高分辨率技术,应作为临床实践中产前诊断先天性心脏病的一线检测。

研究设计与样本

  • 前瞻性研究,在5年期间纳入602例产前先天性心脏病病例,采用单核苷酸多态性微阵列进行分析。

主要发现

  • 602例产前先天性心脏病病例中,125例(20.8%)检出致病性染色体异常,其中52.0%为数目染色体异常。
  • 可能致病性拷贝数变异和意义不明变异的检出率分别为1.3%和6.0%。
  • 先天性心脏病合并其他结构异常组检出率为48.9%,显著高于孤立性先天性心脏病组的14.3%(P < .0001)。
  • 先天性心脏病合并宫内生长迟缓组检出率为50.0%,显著高于孤立性先天性心脏病组的14.3%(P = .044)。
  • 先天性心脏病合并其他结构异常组检出率显著高于先天性心脏病合并软指标组(48.9% vs 19.8%,P < .0001)。

关键数值与推荐

  • 先天性心脏病合并其他结构异常组与先天性心脏病合并宫内生长迟缓组检出率无显著差异(48.9% vs 50.0%)。
  • 先天性心脏病合并软指标组与先天性心脏病合并宫内生长迟缓组检出率无显著差异(19.8% vs 50.0%)。
  • 先天性心脏病合并软指标组与孤立性先天性心脏病组检出率无显著差异(19.8% vs 14.3%)。
  • 先天性心脏病合并轻度脑室扩大胎儿的检出率显著高于其他类型软指标胎儿(50.0% vs 15.6%,P < .05)。

临床怎么用

  • 作者认为染色体微阵列分析应作为产前诊断先天性心脏病的一线检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently, chromosomal microarray analysis is considered the first-tier test in pediatric care and prenatal diagnosis. However, the diagnostic yield of chromosomal microarray analysis for prenatal diagnosis of congenital heart disease has not been evaluated based on a large cohort. OBJECTIVE: Our aim was to evaluate the clinical utility of chromosomal microarray as the first-tier test for chromosomal abnormalities in fetuses with congenital heart disease. STUDY DESIGN: In this prospective study, 602 prenatal cases of congenital heart disease were investigated using single nucleotide polymorphism array over a 5-year period. RESULTS: Overall, pathogenic chromosomal abnormalities were identified in 125 (20.8%) of 602 prenatal cases of congenital heart disease, with 52.0% of them being numerical chromosomal abnormalities. The detection rates of likely pathogenic copy number variations and variants of uncertain significance were 1.3% and 6.0%, respectively. The detection rate of pathogenic chromosomal abnormalities in congenital heart disease plus additional structural anomalies (48.9% vs 14.3%, P < .0001) or intrauterine growth retardation group (50.0% vs 14.3%, P = .044) was significantly higher than that in isolated congenital heart disease group. Additionally, the detection rate in congenital heart disease with additional structural anomalies group was significantly higher than that in congenital heart disease with soft markers group (48.9% vs 19.8%, P < .0001). No significant difference was observed in the detection rates between congenital heart disease with additional structural anomalies and congenital heart disease with intrauterine growth retardation groups (48.9% vs 50.0%), congenital heart disease with soft markers and congenital heart disease with intrauterine growth retardation groups (19.8% vs 50.0%), or congenital heart disease with soft markers and isolated congenital heart disease groups (19.8% vs 14.3%). The detection rate in fetuses with congenital heart disease plus mild ventriculomegaly was significantly higher than in those with other types of soft markers (50.0% vs 15.6%, P < .05). CONCLUSION: Our study suggests chromosomal microarray analysis is a reliable and high-resolution technology and should be used as the first-tier test for prenatal diagnosis of congenital heart disease in clinical practice.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Cao L, Liang D, et al. Prenatal chromosomal microarray analysis in fetuses with congenital heart disease: a prospective cohort study. Am J Obstet Gynecol. 2017. PMID: 29128521. doi:10.1016/j.ajog.2017.10.225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。